Two Mutant Brothers: Why One Gene Change Can Alter Lung Cancer's Fate express

Original: "Time-Varying Hazard Patterns and Co-Mutation Profiles of KRAS G12C and G12D in Real-World NSCLC"

· Robert Amevor, Dennis Baidoo, Emmanuel Kubuafor

arXiv:2602.19295 · 2026-02-22 · CC BY 4.0 · 1 min

The same letter in the KRAS gene, but different swaps: G12C and G12D behave differently in lung cancer patients.

Cancer cells are like broken cars: one glitch makes them drive without stopping. In the KRAS gene, such glitches happen most often. But glitches come in different flavors: the wrong amino acid can sit in one spot of the protein, and that determines how the tumor behaves.

In the new study, two such glitches were compared: G12C and G12D. Patients with G12D had a longer time before the next treatment, especially in the first two years. After two years, the difference fades, but overall survival is still better for G12D. Tumors with G12C more often carry additional glitches in the STK11 and KEAP1 genes, which make the cancer more aggressive.

Both mutations change the same amino acid in the KRAS protein, but to different ones: G12C swaps in cysteine, G12D swaps in aspartic acid. It's like replacing a wheel with a spare tire or a ski: the car is still broken, but it drives differently.

So far, drugs are approved only against G12C, while none exist for G12D. The results suggest we need to develop separate drugs for each mutation. Then treatment becomes more precise, like a key fitting its own lock.

The G12C and G12D mutations differ by just one letter in the DNA, but one makes the tumor sensitive to a drug, while the other does not, yet.

Scientists

Emmy Noether Wolfgang Pauli Enrico Fermi Paul Dirac Chien-Shiung Wu Eugene Wigner

Concepts

mutation CRISPR Standard Model Noether's theorem spin–statistics theorem Fermi's golden rule CPT theorem law of conservation of electric charge Bose–Einstein statistics

I am the author

Two Mutant Brothers: Why One Gene Change Can Alter Lung Cancer's Fate express